Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?

Radiotherapy is a cornerstone of both curative and palliative cancer care. However, radiotherapy is severely limited by radiation-induced toxicities. If these toxicities could be reduced, a greater dose of radiation could be given therefore facilitating a better tumor response. Initial pre-clinical studies have shown that irradiation at dose rates far exceeding those currently used in clinical contexts reduce radiation-induced toxicities whilst maintaining an equivalent tumor response. This is known as the FLASH effect. To date, a single patient has been subjected to FLASH radiotherapy for the treatment of subcutaneous T-cell lymphoma resulting in complete response and minimal toxicities. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy is yet to be elucidated, but the most prominent hypothesis so far proposed is that acute oxygen depletion occurs within the irradiated tissue. This review examines the tissue response to FLASH radiotherapy, critically evaluates the evidence supporting hypotheses surrounding the biological basis of the FLASH effect, and considers the potential for FLASH radiotherapy to be translated into clinical contexts.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Conclusion: ATLL can have rare clinical presentations, a diagnosis of which requires an eye for suspicion and a comprehensive work up. To the best of our knowledge, ATLL presenting with two subsets of CD4+/CD4- populations has not been reported. PMID: 32037902 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
In this study, we used the concept of photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA), a precursor of an endogenously synthesized photosensitizer protoporphyrin IX (PpIX) in combination with blue light to explore the possibility of targeting activated human blood T cells ex vivo. With various T-cell activation protocols, a high ALA-induced PpIX production took place in activated CD3+, CD4+CD25+, and CD8+ T cell populations with their subsequent killing after blue light exposure. By contrast, resting T cells were much less damaged by the treatment. The selective and effective killing effect on the activated cell...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
(University of Alberta Faculty of Medicine&Dentistry) A new study shows cancer cells found in the lesions on the skin of cutaneous T-cell lymphoma patients originate from the blood, not the skin as was believed. The protocol to treat the disease was to eliminate the cancer cells from the skin. Based on the findings, researchers believe it would be more effective to treat the malignant clones in the blood rather than waiting until the cells reach the skin and present as lesions.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Blood Cancer Journal, Published online: 27 January 2020; doi:10.1038/s41408-020-0276-7Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
After publication of our article [1] it was highlighted by the authors that the type of this article was primary research, instead of review.
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Correction Source Type: research
In this study, CSF samples were acquired from hospitalization patients from the Cancer Center of West China Hospital, Chengdu, China. Comparative proteomic profiling are commonly used to do label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS). And in this study the same method was used to characterize the variety of proteins in ENKTL patients and none-ENKTL people.Results: In the aggregate, 421 non-excrescent and functional proteins were identified among the samples. Of these proteins, 45 proteins quantified match the involved criteria. HRG, TIMP-1, SERPINA3, FGA, FGG, TF, FGB, APP, and AGT were significant...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB) Intervention:   Drug: chlormethine gel Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Erica S. Tarabadkar† and Michi M. Shinohara*† Division of Dermatology, University of Washington, Seattle, WA, United States Skin directed therapies (SDTs) serve important roles in the treatment of early stage cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF), as well as managing symptoms and improving quality of life of all stages. There are now numerous options for topical therapies that demonstrate high response rates, particularly in early/limited MF. Phototherapy retains an important role in treating MF, with increasing data supporting efficacy and long-term safety of both UVB and PUVA as ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract BACKGROUND:: Intractable pruritus affects an estimated 83% of patients with advanced cutaneous T-cell lymphoma. Palliative care strategies to improve outcomes for these patients are lacking. Lignocaine antagonises kappa opioid antagonist-induced scratching in mice models and may relieve cutaneous T-cell lymphoma-pruritus. PRACTICE CHALLENGE:: The aim of this retrospective case series was to evaluate our clinical experience with low-dose continuous subcutaneous infusion lignocaine for intractable pruritus associated with cutaneous T-cell lymphoma, from 2000 to 2015. The study received approval from Re...
Source: Palliative Medicine - Category: Palliative Care Authors: Tags: Palliat Med Source Type: research
More News: Cancer | Cancer & Oncology | Lymphoma | Palliative | Study | T-cell Lymphoma | Toxicology